Prime Highlights
- AstraZeneca selects Virginia as its biggest factory globally under a $50 billion US investment strategy.
- Artificial intelligence, robots, and data tech will be used to make drug substance at world-class facility.
Key Facts
- Virginia plant is pharma titan’s biggest single-site manufacturing wager in the world.
- Company targets 50% of US-sourced revenues and $80 billion of group sales by 2030.
Key Background
AstraZeneca invested a record $50 billion in America through 2030, in manufacturing capacity and R&D. The centerpiece of the plans is innovation on a new state-of-the-art facility in Virginia, AstraZeneca’s biggest ever manufacturing site. The facility is a showpiece of AstraZeneca’s strategic investment in building local supply chains, generating high-value jobs, and establishing its base in the U.S. market.
The Virginia plant will have the capacity to produce active pharmaceutical ingredients like small molecules, peptides, and oligonucleotides—essential to managing disease in oncology, cardiovascular, metabolic, respiratory, and rare disease therapy areas. The plant will be a “smart factory” with the application of artificial intelligence, automation, and real-time processing of data to achieve maximum operational excellence and sustainability and product quality. Welcomed by the new manufacturing technologies, AstraZeneca will be reacting sooner to the needs of worldwide health with a lower footprint on the environment.
The government of the state welcomes Virginia’s choice of the historic project with fresh hope at the promise of creation of enormous numbers of jobs and long-term economic growth. Governor Glenn Youngkin underscored the investment as a testament to confidence in Virginia’s talented workforce, transportation network, and business climate. Aside from its domestic economic benefit, the plant also shields America’s pharma supply chain, reducing reliance on foreign production as geopolitical tensions and tariff uncertainty rise.
This expansion falls within AstraZeneca’s goal of achieving 50% of its percentage revenue in the United States at 42% and a share of its total global sales target of $80 billion in 2030. In addition to this anchor campus, the company is investing in other major U.S. locations including Massachusetts, Maryland, Indiana, California, and Texas in both R&D and commercial presence.
Read Also : Enbridge Invests US $900M in Clear Fork Solar Project to Power Meta’s Data Centers
